What is Veracyte?
Founded in 2006 and headquartered in San Francisco, California, Veracyte is at the forefront of molecular cytology. The company develops advanced molecular tests designed to enhance the diagnostic accuracy of cytology samples. By providing more precise diagnostic tools, Veracyte aims to improve patient outcomes and streamline healthcare processes, particularly by increasing the utility of minimally invasive procedures as a viable alternative to surgical biopsies. This focus on innovative diagnostic solutions positions Veracyte as a key player in the evolving landscape of personalized medicine and diagnostic technology.
How much funding has Veracyte raised?
Veracyte has raised a total of $640.9M across 10 funding rounds:
Series B
$28M
Series C
$28M
Stock Offering
$58M
Share Placement
$40M
Debt
$45M
Stock Offering
$31.9M
Stock Offering
$55.1M
Stock Offering
$137.9M
Stock Offering
$194M
Series B (2010): $28M led by KPCB Holdings, Versant Ventures, Domain Associates, and TPG Biotech
Series C (2013): $28M supported by KPCB Holdings, Versant Ventures, Domain Associates, GE Ventures, and TPG Biotech
Stock Issuance/Offering (2013): $58M featuring Undisclosed
Share Placement (2015): $40M backed by Deerfield, Broadfin Capital, Longwood Capital Partners, Camber Capital, and venBio
Debt (2016): $45M with participation from Visium Healthcare Partners
Stock Issuance/Offering (2016): $31.9M led by Undisclosed
Stock Issuance/Offering (2018): $55.1M supported by Undisclosed
Stock Issuance/Offering (2019): $137.9M featuring Undisclosed
Stock Issuance/Offering (2020): $194M backed by Undisclosed
Key Investors in Veracyte
KPCB Holdings
Kleiner Perkins is a Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology and lifescience companies, backing founders across consumer, enterprise, healthcare, and climate/hard tech with capital and operational support from seed through IPO or acquisition.
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies around the world. With over $5.5 billion under management, they have a strong track record that includes over 50 IPOs and M&A transactions. Their experienced team boasts extensive backgrounds in venture capital, pharmaceuticals, and biotechnology, supported by numerous academic partnerships and in-house multi-disciplinary scientific teams. Versant operates from six locations, utilizing state-of-the-art laboratory facilities to drive scientific discoveries and the launch of new biotech ventures.
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets. The firm has provided VC funding to 194 biopharmaceutical, device, and diagnostic companies, resulting in 90 IPOs and 110 M&A events, with a combined market cap of $190 billion for the funded companies. Its intended clients include biotech startups and investors looking to enter the biotech sector.
What's next for Veracyte?
Veracyte's consistent access to capital, including major enterprise-level funding and strategic investments, suggests a robust business model and strong market confidence. The company is well-positioned to further its research and development efforts, expand its product portfolio, and scale its commercial operations. Future strategic moves are likely to involve continued innovation in molecular diagnostics, potentially exploring new disease areas or refining existing technologies to meet unmet clinical needs. The sustained financial support indicates a clear path toward market leadership and continued growth in the biopharmaceutical and diagnostic industries.
See full Veracyte company page
